Want to see PAVM full AI Analyst Report?
PAVM Stock Chart & Stats
$5.28
$0.26(5.49%)
At close: 4:00 PM EDT
$5.28
$0.26(5.49%)
Day’s Range― - ―
52-Week Range$1.84 - $28.44
Previous Close$8
Volume5.54K
Average Volume (3M)22.32K
Market Cap
$17.35M
Enterprise Value$38.63M
Total Cash (Recent Filing)$3.78M
Total Debt (Recent Filing)$17.07M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Nov 17, 2026EPS Estimate
-0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.36
Shares Outstanding7,995,918
10 Day Avg. Volume9,546
30 Day Avg. Volume22,320
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.13
Price to Sales (P/S)62.51
P/FCF Ratio>-0.01
Enterprise Value/Market Cap2.23
Enterprise Value/Revenue344.94
Enterprise Value/Gross Profit-135.55
Enterprise Value/Ebitda-2.37
Forecast
1Y Price Target
$36.50Price Target Upside591.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.14
Revenue Forecast (FY)$182.50K
Bulls Say, Bears Say
Bulls Say
Medicare Reimbursement ProgressMedicare payment initiation is a meaningful structural advance for EsoGuard because reimbursement supports recurring diagnostic revenue and broader clinical adoption. It improves the commercial pathway for Lucid’s testing business and may reduce a major barrier to expanding ordering clinicians and health-system utilization.
Multi-Program Product ProgressProgress across several diagnostic and therapeutic programs gives PAVmed multiple avenues for future commercialization rather than relying on one product. Active clinical, technical and regulatory work across the portfolio can broaden revenue opportunities and create durable operating leverage if adoption milestones are achieved.
Lucid Capital StrengtheningThe $15 million Lucid financing strengthens the subsidiary’s financial flexibility while it expands diagnostic operations and pursues reimbursement-driven growth. Additional capital can support commercialization and investor participation, helping the business fund execution against its longer-term adoption objectives.
Bears Say
Severe Cash BurnPersistent, very large negative operating and free cash flow indicates that the current business is consuming substantial capital relative to its revenue base. This creates continuing funding needs, limits financial flexibility, and raises execution risk while the company works toward scalable commercialization.
Weak Operating EconomicsThe very small revenue base and deeply negative gross margin show that current commercial activity is not yet supporting sustainable unit economics. Continued operating and net losses leave profitability dependent on substantial revenue growth, reimbursement progress and successful product adoption.
Rising Development CostsIncreasing operating and research spending raises the capital required to advance Veris and other programs before they generate meaningful revenue. Unless these investments produce successful regulatory outcomes and commercial uptake, higher costs could prolong losses and intensify pressure on liquidity.
PAVmed News
PAVM FAQ
What was PAVmed Inc’s price range in the past 12 months?
PAVmed Inc lowest stock price was $1.84 and its highest was $28.44 in the past 12 months.
What is PAVmed Inc’s market cap?
PAVmed Inc’s market cap is $17.35M.
When is PAVmed Inc’s upcoming earnings report date?
PAVmed Inc’s upcoming earnings report date is Nov 17, 2026 which is in 24 days.
How were PAVmed Inc’s earnings last quarter?
PAVmed Inc released its earnings results on Aug 14, 2026. The company reported -$0.87 earnings per share for the quarter, missing the consensus estimate of -$0.47 by -$0.4.
Is PAVmed Inc overvalued?
According to Wall Street analysts PAVmed Inc’s price is currently Undervalued.
Does PAVmed Inc pay dividends?
PAVmed Inc does not currently pay dividends.
What is PAVmed Inc’s EPS estimate?
PAVmed Inc’s EPS estimate is -0.59.
How many shares outstanding does PAVmed Inc have?
PAVmed Inc has 7,995,918 shares outstanding.
What happened to PAVmed Inc’s price movement after its last earnings report?
PAVmed Inc reported an EPS of -$0.87 in its last earnings report, missing expectations of -$0.47. Following the earnings report the stock price went up 9.705%.
Which hedge fund is a major shareholder of PAVmed Inc?
Currently, no hedge funds are holding shares in PAVM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PAVmed Inc
PAVmed Inc. operates as a U.S.-based medical technology firm. Its principal commercialized products include CarpX, a percutaneous device designed to address carpal tunnel syndrome. Other key offerings are EsoCheck, an esophageal cell collection device vital for the early detection of esophageal adenocarcinoma and Barrett's Esophagus (BE), and EsoGuard, a specialized bisulfite-converted next-generation sequencing DNA assay. The company's extensive development pipeline further encompasses EsoCure, an esophageal ablation device intended to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; and NextFlo, a disposable infusion platform technology. Also in development are the Veris cancer healthcare platform, which features an intelligent vascular port for combined remote monitoring and data analytics, alongside Veris cardiac monitors. Additional innovations include NextVent single-use ventilators, FlexMO medical circulatory support cannulas, DisappEAR resorbable pediatric ear tubes, and Solys for noninvasive glucose monitoring. Established in 2014, the enterprise originally traded as PAXmed Inc. before rebranding to PAVmed Inc. in April 2015. Its corporate headquarters are located in New York, New York.
PAVM Company Deck
PAVM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted clear operational and technical progress across multiple programs (Lucid reimbursement gains, Veris commercial onboarding and device development milestones, positive first-in-human PortIO data, Octeris technical improvements) and structural financing moves. However, the company faces material near-term liquidity constraints (cash $3.8M) and depends on contingent financing events (warrants tied to a Lucid LCD and Veris FDA clearance), while R&D and operating expenses are rising and key regulatory approvals remain uncertain. Positives demonstrate momentum and multiple potential value catalysts, but funding and regulatory timing introduce significant execution risk.View all PAVM earnings summariesPAVM Stock 12 Month Forecast
Average Price Target
$36.50
▲(591.29% Upside)
Technical Analysis
InspireMD
―
Xtant Medical Holdings
―
Sensus Healthcare
―
TELA Bio
―
QT Imaging Holdings
―
Ownership Overview
12.02% Insiders
0.27% Mutual Funds
5.77% Other Institutional Investors
81.00% Public Companies and
Individual Investors